中国卫生标准管理
中國衛生標準管理
중국위생표준관리
China Health Standard Management
2015年
23期
54-55,56
,共3页
恶性腹水%热灌注%免疫治疗系统
噁性腹水%熱灌註%免疫治療繫統
악성복수%열관주%면역치료계통
Malignant ascites%Hot perfusion%Immunotherapy
目的：热灌注腹腔化疗联合免疫治疗恶性腹水的疗效观察。方法选择我科发展为恶性腹水患者52例，随机分为对照组和治疗组，对照组仅采用热灌注腹腔化疗，治疗组采用热灌注腹腔化疗联合免疫治疗方法。结果对照组有效率72%，治疗组有效率80%，两组比较无明显差异。KPS评分改善率对照组12%，治疗组28%，差异有统计学意义（P <0.05）。结论免疫治疗联合热灌注腹腔化疗治疗恶性腹水较单一应用热灌注腹腔化疗疗效更佳，对化疗后的卡氏评分及骨髓抑制的改善疗效显著。
目的：熱灌註腹腔化療聯閤免疫治療噁性腹水的療效觀察。方法選擇我科髮展為噁性腹水患者52例，隨機分為對照組和治療組，對照組僅採用熱灌註腹腔化療，治療組採用熱灌註腹腔化療聯閤免疫治療方法。結果對照組有效率72%，治療組有效率80%，兩組比較無明顯差異。KPS評分改善率對照組12%，治療組28%，差異有統計學意義（P <0.05）。結論免疫治療聯閤熱灌註腹腔化療治療噁性腹水較單一應用熱灌註腹腔化療療效更佳，對化療後的卡氏評分及骨髓抑製的改善療效顯著。
목적：열관주복강화료연합면역치료악성복수적료효관찰。방법선택아과발전위악성복수환자52례，수궤분위대조조화치료조，대조조부채용열관주복강화료，치료조채용열관주복강화료연합면역치료방법。결과대조조유효솔72%，치료조유효솔80%，량조비교무명현차이。KPS평분개선솔대조조12%，치료조28%，차이유통계학의의（P <0.05）。결론면역치료연합열관주복강화료치료악성복수교단일응용열관주복강화료료효경가，대화료후적잡씨평분급골수억제적개선료효현저。
Objective To observe hot perfusion intraperitoneal chemotherapy combined with immune therapy of malignant ascites.Methods52 patients from our department with malignant ascites were Choosed and randomly divided into control group and treatment group .The control group only used hot perfusion intraperitoneal chemotherapy, the treatment group used hot perfusion intraperitoneal chemotherapy combined with immune therapy.Results The control effectiveness 72%, treatment group effective rate was 80%, no obvious difference was found between two groups. KPS score period in the control group 12%, treatment group was 28%, with significant difference(P < 0.05).ConclusionThe curative effect of immunotherapy combined with hot perfusion intraperitoneal chemotherapy treatment of malignant ascites is better than hot perfusion intraperitoneal chemotherapy,and it can significant improve bone marrow depression after chemotherapy and KPS scores of the patients.
